Abstract:Intramolecular phenol coupling reactions of alkaloids can lead to active metabolites catalyzed by the mammalian cytochrome P450 enzyme (P450); however, the mechanistic knowledge of such an "unusual" process is lacking. This work performs density functional theory computations to reveal the P450-mediated metabolic pathway leading from R-reticuline to the morphine precursor salutaridine by exploring possible intramolecular phenol coupling mechanisms involving diradical coupling, radical addition, and electron transfer. The computed results show that the outer-sphere electron transfer with a high barrier (>20.0 kcal/mol) is unlikely to happen. However, for intersphere intramolecular phenol coupling, it reveals that intramolecular phenol coupling of R-reticuline proceeds via the diradical mechanism consecutively by compound I and protonated compound II of P450 rather than the radical addition mechanism. The existence of a much higher radical rebound barrier than that of H-abstraction in the quartet high-spin state can endow the R- reticuline phenoxy radical with a sufficient lifetime to enable intramolecular phenol coupling, while the H-abstraction/radical rebound mode with a negligible rebound barrier leading to phenol hydroxylation can only happen in the doublet low-spin state. Therefore, the ratio [coupling]/[hydroxylation] can be approximately reflected by the relative yield of the high-spin and low-spin H- abstraction by P450, which thus can provide a theoretical ratio of 16:1 for R-reticuline, which is in accordance with previous experimental results. Especially, the high rebound barrier of the phenoxy radical derived from the weak electron-donating ability of the phenoxy radical is revealed as an intrinsic nature. Therefore, the revealed intramolecular phenol coupling mechanism can be potentially extended to several other bisphenolic drugs to infer groups of unexpected metabolites in organisms.

4,4'-Dihydroxyphenazone as an urinary metabolite of phenazone in different species including man

Preparative isolation and purification of urinary conjugates in antipyrine metabolism in man and rat

Metabolism of debrisoquine sulphate in rat, dog and man

[2-Acetyl-2-methyl-1-phenyl-hydrazine: a frequently occuring artifact in processing biological material after ingestion of drugs containing antipyrine (author's transl)]

Inhibitive Effect of Diphenytriazol on Rat Cytochrome P450 Enzyme in Vitro

Induction of Diphenytriazol on Cytochrome CYP1A.

Metabolic Pathways of Dipfluzine in Rats

[Metabolism-Based Interaction of Diphenytriazol and Flavone Compounds].

Computational Investigation of the Bisphenolic Drug Metabolism by Cytochrome P450: What Factors Favor Intramolecular Phenol Coupling

Benzil 4-Nitrophenylhydrazone

Metabolism, plasma or serum levels, and elimination of phenformin in guinea pigs, rats, and dogs

Phenolic metabolites of chlorprothixene in man and dog

Species- and sex-related differences in the plasma clearance and metabolite formation of antipyrine. A comparative study in four animal species: cattle, goat, rat and rabbit

Urinary excretion of 4-hydroxyphenyllactic acids and related compounds in man, including a screening test for tyrosyluria

Metabolism of p-hydroxybenzoic acid and p-hydroxyphenylacetic acid in the monkey

Detection and identification of human urinary metabolites of biantrazole (CI-941)

IDENTIFICATION OF HYDROXYLATED METABOLITE OF SFZ-47, A NOVEL ANTI-INFLAMMATORY AND ANALGESIC AGENT, AND ITS CONJUGATES IN RABBITS

Identification of the major metabolites of 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one, a new angiotensin type 1 receptor antagonist, in rat bile by HPLC-diode array detection-MS and HPLC-MS/MS.

2,5-Dihydroxy-4-methoxybenzophenone: a novel major in vitro metabolite of benzophenone-3 formed by rat and human liver microsomes

Methods for study of fluphenazine kinetics in man

High-performance Liquid Chromatographic Determination of Urinary 4′-Hydroxymephenytoin, a Metabolic Marker for the Hepatic Enzyme CYP2C19, in Humans